CGTX
Cognition Therapeutics, Inc.
There isn't enough reported data to score CGTX yet.
CGTX Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
CGTX's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
CGTX PE Valuation
CGTX has no meaningful PE right now: it lost money over the past year.
CGTX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| -- | |
| -- | |
| Limited | |
| Low |
Analysts expect CGTX's losses to shrink, with revenue holding steady. However, they disagree widely on these estimates.
CGTX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.17 | +$0.30 |
| Q2 2026 | -$0.19 | +$0.47 |
| Q1 2026 | -$0.26 | +$0.47 |
| Q4 2025 | -$0.35 | +$0.51 |
| Q3 2025 | -$0.47 | +$0.50 |
| Q2 2025 | -$0.66 | +$0.28 |
| Q1 2025 | -$0.73 | +$0.19 |
| Q4 2024 | -$0.86 | $0.00 |
CGTX is still losing money, but far less than before: $0.17 per share over the past year, against $0.97 at its worst in late 2024.
CGTX Quarterly Revenue
CGTX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$5.5M | +$4.3M |
| Q4 2024 | -$8.4M | -$2.9M |
| Q3 2024 | -$6.9M | -$2.6M |
| Q4 2023 | -$5.5M | +$4.7M |
| Q3 2023 | -$4.2M | -$4.2M |
| Q2 2023 | -$3.7M | +$1.6M |
| Q1 2023 | -$2.7M | +$376K |
| Q2 2022 | -$5.4M | -$4.5M |
CGTX has burned cash in almost every quarter: −$27M over the past year, against −$20M the year before.
CGTX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +4.9% | +4.5M shares |
| 1 year | +22% | +17.1M shares |
| 3 years | +227% | +66M shares |
CGTX has 95M diluted shares, up 22% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2021 | — |
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
CGTX Net Leverage
CGTX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
CGTX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.6 | Neutral |
| Stochastic | 11.0 | Oversold |
CGTX's weekly RSI is 35 (neutral) and its Stochastic is 11 (oversold).
CGTX PE vs Healthcare Sector
CGTX has no meaningful PE right now: it lost money over the past year.
CGTX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.78 | 13% below |
| 20 week MA | $0.92 | 26% below |
| 50 week MA | $1.11 | 39% below |
| 100 week MA | $1.02 | 33% below |
| 200 week MA | $1.30 | 48% below |
CGTX is in a downtrend: it's below all five of its weekly moving averages, and 48% below its 200-week average.
CGTX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $12.8 | $6.16 | -52% |
| 2022 | $6.16 | $2.36 | -62% |
| 2023 | $2.36 | $1.85 | -22% |
| 2024 | $1.85 | $0.84 | -55% |
| 2025 | $0.84 | $1.45 | +73% |
| 2026 YTD | $1.45 | $0.68 | -53% |
CGTX has finished lower in four of the last five years. It's down 53% so far in 2026.